Introduction
As a consequence of the environment in which they exist, cells in highly oxidative tissues must continuously manage the burden of electrophilic aldehydes. Biogenic aldehydes are defined as those that are formed endogenously via spontaneous and enzyme-dependent oxidation of glucose, unsaturated lipids, primary amines, and other less-abundant substrates. If not metabolized by detoxification enzymes in the cell, biogenic aldehydes can become toxic due to excessive covalent modification of proteins (typically on Cys, Lys and His residues), DNA, and phospholipids. It is presumed that this reaction is irreversible, since at the present time, no enzymes capable of reversing this modification have been identified.
Because of the vast differences in chemical structure and site of formation, aldehydes differ in their reactivity and overall signaling effects in cells. This topic has a rich history and remains a very active area of research in biochemistry. Biogenic aldehydes are increasingly being recognized as major factors underlying cardiovascular disease, although the precise sources, reactivity, and pathological mechanisms by which they act remain obscure. A concise overview of the major deleterious effects of biogenic aldehydes in the cardiovascular system is provided in Figure 1 . Probably the most convincing evidence in support of a pathological role is that pharmaceutical agents that blunt aldehyde formation, buffer/ scavenge aldehydes directly via conjugation, or increase aldehyde metabolism have demonstrated beneficial effects for numerous cardiovascular diseases.
Since much of the biochemistry of biogenic aldehyde formation, cellular toxicity, and signaling effects in cells have been extensively reviewed in recent years [1,2 ,3 ] , this review will focus specifically on the major known sources of biogenic aldehydes that have been described in cardiovascular pathophysiology. A brief summary of the drugs and nutraceutical compounds known to have aldehyde-trapping and therapeutic effect in cardiovascular diseases will follow.
Sources of biogenic aldehydes within the cardiovascular system
In most biological systems, the prominent source of biogenic aldehydes is the oxidation of sugars and lipids. When glucose undergoes autoxidation, the formation of Schiff base and subsequent Amadori product rearrangement generates glyoxal, methylglyoxal, and 3-deoxyglucasone [4] [5] [6] . Rearrangement and fragmentation of oxidized polyunsaturated fatty acids (PUFAs) also generates these aldehydes, in addition to a,b-unsaturated aldehydes, such as 4-hydroxynonenal (HNE) and 4-hydroxyhexenal (HHE), malondialdehyde, and keto-aldehydes [7, 8 ] . Since many phospholipids within cellular membranes contain PUFAs, it is the membranes that initially are the source of lipid peroxidation, typically initiated by the superoxide radical (O 2 À ). Because of their proximity to blood, cells and tissues within the cardiovascular system are continuously exposed to some of the highest O 2 concentrations within the body. Consequently, since the rate of O 2 À production and subsequent reactive oxygen species (ROS) formation is directly proportional to O 2 concentration [9 ] , cardiovascular tissues are susceptible to very high levels of spontaneous lipid and glucose oxidation.
Enzymatic oxidation of lipids and sugars is another pathway of biogenic aldehyde formation. Methylglyoxal (MGO) can be formed through methylglyoxal synthase, myeloperoxidase, and members of the cytochrome P450 superfamily [5] . Although beyond the scope of this review, there are numerous oxygenases within the prostaglandin pathway that catalyze the oxidation of PUFAs [10] . The products of these oxygenase-dependent reactions are typically more stable than the lipid peroxides formed via ROS, but are still capable of rearrangement and breakdown, thus making them sources of biogenic aldehydes.
Another endogenous source of biogenic aldehydes within the cardiovascular system comes from enzymatic metabolism of primary amines. Oxidative deamination of norepinephrine (NE) and dopamine (DA) by monoamine oxidase (MAO) produces the catecholaldehydes 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) and 3,4-dihydroxyphenylacetaldehyde (DOPAL), respectively, and H 2 O 2 [11] . Both DOPEGAL and DOPAL have been demonstrated to be far more cytotoxic and reactive than the parent catecholamines or any downstream metabolites. The surprisingly high reactivity and toxicity appears to stem from the reactivity of both catechol and aldehyde groups [12 ] . Although a direct link between catecholaldehydes and cardiovascular disease remains to be elucidated, work in clinical and experimental models have documented a pathological role for MAO in cardiac injury from ischemia, diabetes, and hypertension [13] [14] [15] .
As a protective mechanism, cells maintain an array of detoxification enzymes that are tasked with metabolism and removal of biogenic aldehydes. These enzymes include aldehyde dehydrogenase, aldose reductase, carbonyl reductase, aldehyde reductase, and enzymes in the glutathione-dependent family [16] . However, this network of enzymes can be overwhelmed during periods of acute (e.g., ischemia, sepsis) and chronic cardio-metabolic stress (e.g., hypertension, diabetes) [2 ] . Because of their high reactivity and potential for covalent modification of proteins and DNA, particularly cross-linking aldehydes such as glyoxal and catecholaldehyde, it has become evident that therapeutic strategies are needed that can buffer endogenous levels of biogenic aldehydes via conjugation.
Clinically approved agents with aldehyde scavenging capacities
The focus of this review includes drugs that have been approved for treatment of metabolic or cardiovascular diseases that have also been found to possess auxiliary aldehyde-conjugating properties. Such drugs are of great interest since the safety profile and pharmacodynamics/kinetics have already been established and, moreover, these agents are potentially included in regimens of patients diagnosed with cardiovascular diseases (Table 1) .
Metformin
Metformin is approved and recommended as a first-line agent to treat type 2 diabetes [17] . Similar in structure to aminoguanidine, the guanidino group of metformin putatively confers anti-glycating and aldehyde-conjugating abilities [18] . In a clinical study of recently diagnosed type 2 diabetes-mellitus (T2DM) patients, metformin treatment was found to not only decrease advance oxidation protein products within plasma, but proved more beneficial in reducing circulating advanced glycation endproducts (AGEs) compared to lifestyle modification alone [19] . In a smaller subset of T2DM patients, metformin therapy protected ApoB100 of LDL cholesterol against oxidative and glycated damage caused by AGEs [20] . Parallel findings were obtained in a T2DM rat model of diabetes, wherein metformin treatment decreased vascular AGE deposition and reversed diabetes-induced endothelial dysfunction within aortic sections [21] . In a recent study, Kinsky et al. examined urine samples from 92 metformin-treated T2DM patients and reported a strong positive correlation between oral metformin concentration and metformin-MGO conjugate levels in urine [22] , suggesting that metformin scavenges and enhances renal excretion of MGO. In addition to its known mechanism of actions, such studies suggest a secondary therapeutic effect of metformin as an AGE scavenger.
Hydralazine
Hydralazine is approved for use as an anti-hypertensive medication and, since its discovery, has also been investigated as a scavenger of carbonyl species. Hydralazine contains a nucleophilic hydrazine moiety which binds with free and protein-bound aldehydes to form stable hydrazones [23, 24 ]. In animal models of atherosclerosis, hydralazine administration was found to reduce atherosclerotic lesion size and decrease carbonyl protein adducts within aortic sinuses, suggesting hydralazine possesses anti-atherogenic properties. [25, 26] . Similar findings were observed within a streptozotocin mouse model of type 1 diabetes (T1DM) where hydralazine inhibited both formation and protein adduction of AGEs in plasma and kidney proteins. Within the same study, hydralazine decreased renal expression of receptor for AGE (rAGE) and NADPH oxidase (NOX), an interesting finding as these protein targets are upregulated via AGE activation and involved in AGE-rAGE mediated ROS production [27 ] . Although translational studies investigating the aldehyde-scavenging abilities of hydralazine are limited, results from animal studies provide strong evidence that hydralazine is beneficial in sequestering biogenic aldehydes, thereby preventing downstream oxidative stress and vascular damage.
Edaravone
In 2001, Japan approved the use of Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one, MCI-186) as a free radical scavenger for the treatment of acute ischemic stroke. The effectiveness of edaravone as an antioxidant is in its ability to quench hydroxyl radicals and inhibit hydroxyldependent lipid peroxidation [28, 29] . More recently, the focus of edaravone research has shifted to mitigating the pathogenic activity of biogenic aldehydes within cardiovascular diseases.
Several clinical studies have reported benefits of edaravone administration in patients with acute coronary infarct. When given 10 min before reperfusion, edaravone therapy chronically improved left ventricle ejection fraction (LVEF), decreased infarct size and reduced occurrence of reperfusion-associated ventricular tachyarrhythmias. In addition, plasma biomarkers measured after edaravone administration revealed a decrease in plasma creatine kinase (CK-MB), serum thioredoxin levels, and levels of monocyte chemoattractant protein-1 (MCP-1), a major chemokine involved in the vascular inflammatory response [30] . Although biogenic aldehydes were not measured in these studies, when used in a mouse model of atherosclerosis, edaravone treatment decreased circulating plasma isoprostane levels and decreased levels of 4-HNE within aortic atherosclerotic lesions [32] proposing that the sequestering of aldehydes by edaravone attenuates mechanical and oxidative damage associated with myocardial ischemia. Arginine-derived AGE and protein modified methionine residue levels of apolipoprotein B100 of LDL were reduced in diabetic patients receiving metformin compared to diabetic patients not receiving metformin The edaravone group showed decrease infarct size and lower incidences of reperfusion arrhythmia. Post-reperfusion plasma thioredoxin levels were significantly reduced in the edaravone treated group [31] Pyridoxamine (100 mg/day for 24 weeks OR 500 mg/day for 20 weeks)
T1DM and T2DM individuals with mild/moderate diabetic nephropathy Placebo (n = 63) 100 mg/day pyridoxamine (n = 65) OR Placebo (n = 27) 500 mg/day pyridoxamine (n = 57)
Pooled data from both phase II studies showed pyridoxamine treatment lowered plasma AGE levels and improved creatinine clearance Patients who received L-carnosine showed an improved peak VO 2 and increased cardiac functional capacity
Pyridoxamine
As a derivative of vitamin B 6 , pyridoxamine is critically involved in both the early and late stages of AGE formation [33] . Within several rat models of T1DM, pyridoxamine decreased circulating levels of triglyercides, total cholesterol, and AGEs and advanced lipoxidation endproducts (ALEs) [34] . In a similar study investigating the cardiac effects of diabetes, diastolic dysfunction,aberrant Ca 2+ concentrations, and carbonyl modifications of SERCA, were observed within diabetic rat hearts. Importantly, diabetic rats treated with pyridoxamine retained diastolic function and SERCA activity and showed decreased levels of AGEs and ALEs within ventricular sections [35] . A study by Jain et al. investigated the effect of isolated human erythrocytes in high glucose medium co-incubated with pyridoxamine and observed reduced hydroxyl radical production, glycated hemoglobin, and lipid peroxidation, and furthermore sustained Na + /K + -ATPase activity compared to non-pyridoxamine treated cells [36] . Collectively, these studies support pyridoxamine as an exploratory treatment to attenuate cardiac dysfunction and hyperlipidemia observed within diabetes. Although clinical trials investigating pyridoxamine as a treatment for diabetic nephropathy were terminated after phase II [37 ] , current trials are ongoing to determine the efficacy of pyridoxamine on insulin sensitivity and microvasculature function in obese patients.
Nutraceuticals as biogenic aldehyde scavengers Polyphenols
Several epidemiological studies suggested that consumption of polyphenol rich diet reduces the incidence of cardiovascular diseases [38, 39] . Polyphenols are plant metabolites that are present in fruits and vegetables, of which flavonoids are an important class. Flavonoids are polycyclic antioxidants composed of C 6 -C 3 -C 6 ring. The phenolic hydroxyl group of these compounds donates active hydrogen atoms and thus prevents formation of lipid peroxidation products.
Although in-vitro and intervention studies in rat models of hypertension suggest that flavonoids prevents oxidative stress and reduces left ventricular hypertrophy [40, 41] clinical studies in humans failed to show effectiveness in preventing cardiovascular diseases [42] . In a randomized, double-blind placebo-controlled trial (RCT) with grade 1 hypertension, consumption of red wine (280 ml or 560 ml/day for 4 weeks) did not show any effects on ambulatory blood pressure and pulse wave reflection indexes [43] . In a second RCT with 69 treated hypertensive subjects, supplementation with Vitamin C (500 mg/ day) and grape seed extract (1000 mg/day) for 6 weeks [44 ] had no effect on blood pressure. Similarly, supplementation of freeze-dried strawberry extract (50 g/day for 8 weeks) to subjects with metabolic syndrome showed no effects on serum glucose, blood pressure or waist circumference [45] . From these studies, it seems that the cardiovascular disease goes beyond oxidative stress, and anti-oxidative properties of polyphenols are not enough to circumvent these effects.
Carnosine
Reactive aldehydes are also removed by endogenous nucleophiles such as glutathione and histidyl dipeptides such as carnosine and anserine [46, 47] . Carnosine (b-alanine + histidine) is abundantly present in the skeletal muscle, heart and brain, and is synthesized by the ATP grasp enzyme carnosine synthase (ATPGD1) [48, 49] . The homeostasis of this dipeptide in the skeletal muscle is maintained by transporters PHT1, PEPT2 and Taut [50] [51] [52] . In addition to its ability to react with HNE and acrolein, carnosine chelates transition metals, for example, Cu 2+ and Fe 2+ , and buffers intracellular pH [53] .
Dietary supplementation of carnosine has been shown to play a neuroprotective role in focal cerebral ischemia, attenuate development of dyslipidemia, hypertension and carbonyl stress in obese Zucker rats [54] , and decrease atherosclerotic lesion formation and accumulation of HNE, acrolein protein adducts in the lesions of apo E À/À mice [55] . Studies from our laboratory and others have shown that carnosine imparts cardio-protection in isolated rat and mice hearts during ischemia/reperfusion (I/R) injury [46, 56] . Similarly, cardio-specific overexpression of ATPGD1 enhances carnosine levels in cardiac tissue and decreases infarct size during I/R injury (unpublished results). Recent clinical studies with human heart failure patients have suggested that supplementation of carnosine for 6 months improves exercise performance and quality of life in these subjects [57] and administration of carnosine to obese individuals improves glucose uptake [58 ] and increases the extrusion of urinary carnosine-acrolein conjugates in these subjects [59] . Accumulated mechanistic data suggests that the potential of carnosine in treating metabolic and cardiovascular diseases is due to conjugation of reactive carbonyl species. In addition to their synthesis and abundance in vivo, the fact that these histidyl-dipeptides are food constituents with medicinal value makes them ideal candidates for the prevention and treatment of cardiovascular diseases.
Conclusion
Although the clear benefit and need for aldehyde-conjugating therapies exists for cardiovascular disease, many compounds fail during clinical trials due to inefficacy or unforeseeable safety concerns. Translational studies and clinical trials have documented that commonly prescribed cardiovascular drugs such as metformin and hydralazine are capable of mitigating aldehyde-adduct formation and promote aldehyde conjugation. While the therapeutic benefits of these drugs are unquestionable, newer aldehyde-conjugating therapies such as edaravone, pyridoxamine and nutraceutical compounds (e.g., carnosine) require further study and evaluation.
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